中国绝经后女性骨质疏松治疗干预阈值的成本效益分析
本研究基于中国绝经后女性真实世界数据构建微观模拟马尔可夫模型,评估唑来膦酸治疗的成本效益。结果显示,当FRAX评估的10年主要骨质疏松性骨折概率超过7%时,唑来膦酸治疗具有成本效益;该阈值随年龄从51岁至65岁升高而增加,在老年组下降,范围为4%至9%。
要点
- 基于FRAX的10年主要骨质疏松性骨折概率>7%时,唑来膦酸治疗具有成本效益。
- 干预阈值随年龄变化:51至65岁升高,老年组下降,范围4%–9%。
- 广泛使用唑来膦酸对中国绝经后女性具有临床和经济双重获益。
核心结论
- 在中国绝经后女性中,当FRAX评估的10年主要骨质疏松性骨折概率超过7%时,唑来膦酸治疗具有成本效益。
研究设计与样本
- 构建微观模拟马尔可夫模型,模拟骨质疏松状态及髋部、椎体和腕部骨折。
- 基线特征来自北京椎体骨折研究这一中国最大规模绝经后女性前瞻性队列。
- 比较无治疗与唑来膦酸治疗两种情景,计算质量调整生命年(QALY)和总成本。
主要发现
- 基于FRAX的10年主要骨质疏松性骨折概率超过7%时,唑来膦酸治疗具有成本效益。
- FRAX阈值随年龄从51岁至65岁增加而升高,在老年组下降,范围为4%至9%。
关键数值与推荐
- FRAX-based干预阈值:10年主要骨质疏松性骨折概率>7%时推荐唑来膦酸治疗。
- 阈值随年龄变化范围为4%至9%。
临床怎么用
- 对中国绝经后女性,可采用FRAX评估10年主要骨质疏松性骨折概率,超过7%时考虑唑来膦酸治疗以实现成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study built a micro-simulation Markov model to determine the treatment threshold of osteoporosis in postmenopausal women in Mainland China. Treatment with zoledronate is cost-effective when FRAX-based (Fracture risk assessment tool) fracture probability is over 7%. INTRODUCTION: The purpose of this study is to estimate FRAX-based fracture probabilities in Mainland China using real-world data, at which intervention could be cost-effective. METHODS: We developed a micro-simulation Markov model to capture osteoporosis states and relevant morbidities including hip fracture, vertebral fracture, and wrist fracture. Baseline characteristics including incidences of osteoporosis and distribution of risk factors were derived from the Peking Vertebral Fracture study, the largest prospective cohort study of postmenopausal women in Mainland China. We projected incidences of fractures and deaths by age groups under two treatment scenarios: 1) no treatment, and 2) zoledronate. We also projected total quality-adjusted life-years (QALY) and total costs including fracture management and osteoporosis drugs for cost-effectiveness analysis. Cost-effective intervention thresholds were calculated based on the Chinese FRAX model. RESULTS: Treatment with zoledronate was cost-effective when the 10-year probability of major osteoporotic fracture based on FRAX was above 7%. The FRAX threshold increased by age from 51 to 65 years old, and decreased in elder age groups, ranging from 4% to 9%. CONCLUSIONS: Using real-world data, our model indicated that widespread use of zoledronate was of both clinical and economic benefit among Chinese postmenopausal women. Using a FRAX-based intervention threshold of 7% with zoledronate should permit cost-effective access to therapy to patients and contribute to reducing the disease burden of osteoporosis in Mainland China.
引用
- Cui L, He T, Jiang Y, et al. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data. Osteoporos Int. 2019. PMID: 31754756. doi:10.1007/s00198-019-05173-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。